
|Articles|September 16, 2008
- May 15 2003
- Volume 10
- Issue 9
NOT AS SIMPLE AS ABC
Author(s)Michael Sheehan
Advertisement
If you're in the market for mutualfunds but balk at an upfront salesload, your broker may try to talk youinto funds that have "no sales commission."Don't be fooled. If you fallfor that pitch, you'll probably end upwith a fund's B or C shares, whichdon't charge a front-end load, butmake up for it through higherexpense ratios. B shares also charge aback-end load if you sell out within acertain time period, usually 6 or 7years. True no-load funds, whichdon't charge any front-end or back-endfees, are often sold directly toinvestors, not through brokers.
Articles in this issue
about 18 years ago
Postwar Economy Refocuses Attentionabout 18 years ago
Model Portfolio Series: Conservative Growthabout 18 years ago
How Does Your Financial IQ Measure Up?about 18 years ago
History Provides Lessons in Investingabout 18 years ago
Read the Market's Long-Term Performanceabout 18 years ago
Less Is More When Buying Stock Spinoffsabout 18 years ago
Weigh the Aspects of Variable Annuitiesabout 18 years ago
Maximize Your Sale of Stocks at a Lossabout 18 years ago
Realize the Importance of Market Timingabout 18 years ago
Speed Through Annual Reports Like a ProAdvertisement
Related to this article

Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.

Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5

